Incyte
INCY129.9309.30% ( +11.060 )
Q2 FY2026 EarningsQ2 2026 total revenue reached $1.67B, up 38% YoY, primarily driven by a 40% increase in total net sales to $1.49B. A one-time $246M non-cash benefit from a CMS settlement significantly boosted Opzelura sales (+173% YoY); excluding this, core net sales grew 17% YoY. Jakafi remained the top contributor at $817M (+7% YoY), while the Hematology/Oncology portfolio surged 69% to $222M. GAAP diluted EPS rose to $2.81 from $2.04, and the company raised full-year FY2026 net sales guidance to $5.13B - $5.26B.
Financial report interval: 2026.03.30 - 2026.06.30
Preview: Incyte(INCY) predict that the Revenue is 1.674 B (+37.72%), Beat estimate;the EBIT is 773.04 M (+102.1%), Beat estimate;the EPS is 2.81 (+37.75%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
1.67B37.72%
1.49B22.54%
+0.18B15.18%
EBITExceed expectations
0.77B102.06%
0.56B45.69%
+0.22B56.37%
EPSExceed expectations
2.8137.75%
2.21468.56%
+0.595429.19%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf